Gankyrin is a novel biomarker for disease progression and prognosis of patients with renal cell carcinoma

BACKGROUND: In the clinic, how to stratify renal cell carcinoma (RCC) patients with different risks and to accurately predict their prognostic outcome remains a crucial issue. In this study, we assessed the expression and prognostic value of gankyrin in RCC patients. METHODS: The expression of ganky...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chao, Li, Yan, Chu, Chuan-min, Zhang, Xiang-min, Ma, Jie, Huang, Hai, Wang, Yu-ning, Hong, Tian-yu, Zhang, Jing, Pan, Xiu-wu, Zheng, Jing-cun, Jiang, Ning, Hu, Chuan-yi, Ma, Xiaojing, Sun, Ying-hao, Cui, Xin-gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354735/
https://www.ncbi.nlm.nih.gov/pubmed/30558998
http://dx.doi.org/10.1016/j.ebiom.2018.12.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354735/
https://www.ncbi.nlm.nih.gov/pubmed/30558998
http://dx.doi.org/10.1016/j.ebiom.2018.12.011

Ejemplares similares